Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Lessons From Lockdown: Perspectives on Hepatitis C Care in the US and Australia
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: October 1, 2021 Expiration: September 30, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
AbbVie
Gilead Sciences, Inc.
Gregory Dore, MBBS, PhD, FRACP, MPH
Stacey Trooskin, MD, PhD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Adapt clinical practice to better serve the needs of persons with chronic HCV infection in the time of COVID-19

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Gregory Dore, MBBS, PhD, FRACP, MPH

Professor, Head
Viral Hepatitis Clinical Research Program
Kirby Institute
University of New South Wales
Professor
Infectious Diseases Physician
St Vincent's Hospital
Sydney, Australia

Greg Dore, MBBS, PhD, FRACP, MPH, has no relevant conflicts of interest to report.
Stacey Trooskin, MD, PhD, MPH

Chief Medical Officer
Philadelphia FIGHT Community Health Centers
Faculty
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Stacey Trooskin, MD, PhD, MPH, has disclosed that she has received funds for research support and consulting fees from Gilead Sciences

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report
Jennifer Swanson, PharmD

Editorial Contributor

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for patients with viral hepatitis.

Goal

The goal of this activity is to enable learners to adapt their patient care strategies to continue to provide high-quality care for patients with viral hepatitis despite the impact of the COVID-19 pandemic.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-184-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 01, 2021, through September 30, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Lessons From Lockdown: Perspectives on Hepatitis C Care in the US and Australia
  • CME
  • CE

Loading...
In this call between colleagues, expert faculty discuss what they learned during the COVID-19 pandemic about strategies to care for patients with HCV infection, including patients who inject drugs.
Gregory Dore, MBBS, PhD, FRACP, MPH
Stacey Trooskin, MD, PhD, MPH
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: October 1, 2021 Expiration: September 30, 2022

Related Content

Clinical Care Options (CCO) expert analysis by Dr. Nancy Reau on new viral hepatitis data from AASLD 2021, including HBV, HCV, and hepatitis delta

Nancy Reau, MD Released: December 3, 2021

Complimentary slides from CCO featuring an in-depth analysis of HCV burden and care disparities in specific populations and strategies to reduce disparities.

Released: December 1, 2021

Expert insights on special considerations for individuals with HCV in ethnically diverse populations, from Ahmed M. Elsharkawy PhD, FRCP(UK), and Clinical Care Options (CCO)

person default Ahmed M. Elsharkawy, PhD, FRCP(UK) Released: December 1, 2021

Clinical Care Options (CCO) podcast with Dr. Nancy Reau on new viral hepatitis data from AASLD 2021, including HBV, HCV, and hepatitis delta

Nancy Reau, MD Released: December 1, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
AbbVie
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue